APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
Status:
RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are:
Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.
Phase:
PHASE3
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)